Skip to main content

Table 2 Treatment Effects by Group

From: Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Variable Δ Metformin(N = 25) Δ Exenatide(N = 25) Difference(M – E) P-Value
BMI (kg/m2) −0.4 ± 0.7* −0.8 ± 1.4* −0.4 0.229
Waist Circumference (cm) −1.7 ± 3.5* −3.2 ± 6.2* −1.5 0.285
Body Fat (%) 0.8 ± 1.7 0.8 ± 2.6 0.0 0.939
SBP (mmHg) 0.5 ± 10.2 −5.4 ± 15.3 −5.9 0.114
DBP (mmHg) −0.8 ± 6.9 −2.8 ± 7.3 −2.0 0.322
Cholesterol (mg/dL) −9.2 ± 16.1** −14.6 ± 17.4*** −5.4 0.264
LDL-Cholesterol (mg/dL) −1.1 ± 21.4 −9.9 ± 22.5* −8.8 0.169
HDL-Cholesterol (mg/dL) −1.5 ± 9.7 −1.1 ± 12.8 0.4 0.901
Triglycerides (mg/dL) −2.9 ± 22.8 −25.5 ± 45.7* −22.6 0.032
Glucose (mg/dL) −3.7 ± 9.3 −2.7 ± 9.9 1.0 0.725
Insulin (mU/L) −2.4 ± 4.3** −0.6 ± 2.8 1.8 0.079
HOMA-IR −0.8 ± 1.4* −0.2 ± 0.8 0.6 0.094
CRP (mg/L) −0.4 ± 2.2 −0.4 ± 2.2 0.0 0.987
OxLDL (U/L) −16.5 ± 30.4* −0.1 ± 41.5 16.4 0.123
VCAM-1 (ng/mL) −15.3 ± 101.3 10.4 ± 83.2 25.7 0.336
RHI −0.17 ± 0.72 0.01 ± 0.68 0.18 0.348
  1. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low density lipoprotein; HDL = high density lipoprotein; HOMA-IR = homeostasis model assessment for insulin resistance; CRP = C-reactive protein; OxLDL = oxidized low density lipoprotein; VCAM-1 = vascular cell adhesion molecule-1; RHI = reactive hyperemic index.
  2. Data are shown as mean ± standard deviation; P-Values represent ANOVA interaction term.
  3. Body fat data were obtained in 35 patients (exenatide N = 17; metformin N = 18).
  4. * denotes P<0.05 for within group treatment effect; ** denotes P<0.01 for within group treatment effect; *** denotes P<0.001 for within group treatment effect.